title: Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.
abstract: Some patients with early-stage cirrhosis preserve hepatic function, whereas others have little hepatic reserve and rapidly deteriorate. The aim of this study was to use quantitative tests of liver function (QLFTs) to define the degree of functional hepatic impairment in patients with early-stage cirrhosis (Child-Pugh score 5-7) and to determine whether the tests predicted subsequent hepatic decompensation. We recruited 10 cirrhotic (Cr) patients and 10 healthy controls (NI), who were well matched for race, age, weight, and gender. Clearances of caffeine (CF) and antipyrine (AP) after oral administration were measured from timed samples of saliva. The clearance of cholate (CA) was measured from serum samples obtained after simultaneous oral ([2,2,4,4-2H]CA) and intravenous ([24-13C]CA) administration. CA shunt was calculated as (Cl i.v./Clo x 100%). CF elimination rate (Cr v NI, mean +/- SD: 0.03 +/- 0.02 v 0.075 +/- 0.018 h-1, P < .0005) and AP clearance (24 +/- 16 v 40 +/- 7 mL/minute, P < .02) were reduced in Cr patients. CA shunt was increased in Cr patients (43 +/- 18 v 18 +/- 7%, P < .002). Five Cr patients decompensated during follow-up and had the worst CA shunts (76%, 66%, 51%, 48%, and 45%). Three subsequently received successful orthotopic liver transplantation, 1 died of hepatoma, and 1 is on the waiting list for transplantation. In conclusion, QLFTs define the degree of functional impairment in early cirrhosis and may identify Cr patients at greatest risk of decompensation who may require transplantation for survival.
authors.affiliation: Department of Medicine, University of Colorado School of Medicine, Denver 80262, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shrestha
authors.forename: C
authors.initials: C
authors.lastname: McKinley
authors.forename: R
authors.initials: R
authors.lastname: Showalter
authors.forename: K
authors.initials: K
authors.lastname: Wilner
authors.forename: L
authors.initials: L
authors.lastname: Marsano
authors.forename: B
authors.initials: B
authors.lastname: Vivian
authors.forename: G T
authors.initials: GT
authors.lastname: Everson
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000493:pharmacokinetics; D002110:Caffeine / Q000493:pharmacokinetics; D019826:Cholic Acid; D002793:Cholic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D018450:Disease Progression; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000378:metabolism*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D002793:Cholic Acids; D002110:Caffeine; D019826:Cholic Acid; D000983:Antipyrine